Novo Nordisk offers Wegovy for less than half the price through new direct-to-consumer pharmacy
The pharmacy, called NovoCare, will allow patients to pay $499 in cash per month for the blockbuster weight loss drug.
Nordisk
since
auto-detected in 451 stories
65 days ago
Novo Nordisk offers Wegovy for less than half the price through new direct-to-consumer pharmacy
The pharmacy, called NovoCare, will allow patients to pay $499 in cash per month for the blockbuster weight loss drug.
Novo Nordisk offers Wegovy for less than half the price through new direct-to-consumer pharmacy
The pharmacy, called NovoCare, will allow patients to pay $499 in cash per month for the blockbuster weight loss drug.
3 months ago
Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs
found
Ozempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.
Novo Nordisk shares rise on fourth-quarter profit beat, Wegovy sales jump
Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs.
Novo Nordisk shares rise on fourth-quarter profit beat, Wegovy sales jump
Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs.
Novo Nordisk shares gain 4.5% on fourth-quarter profit beat, Wegovy sales jump
Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs.
Novo Nordisk shares gain 4.5% on fourth-quarter profit beat, Wegovy sales jump
Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs.
Novo Nordisk shares jump up on latest weight loss trial results
People treated with amycretin lost up to 22% of their body weight after 36 weeks
4 months ago
Novo Nordisk’s drug stumble leaves it suddenly much slimmer
Market will never be winner takes all given that different patients will have different requirements
|← first ← previous page 4 of 5 next → last →|